Bio-Rad Laboratories, Inc. (NYSE:BIO)‘s stock had its “buy” rating reiterated by Deutsche Bank AG in a report released on Monday. They currently have a $255.00 target price on the medical research company’s stock. Deutsche Bank AG’s target price would suggest a potential upside of 10.70% from the company’s current price.

Several other equities research analysts have also recently issued reports on BIO. BidaskClub cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, June 14th. Zacks Investment Research lowered shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 5th. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price target on the stock. Jefferies Group LLC restated a “buy” rating and issued a $275.00 price target on shares of Bio-Rad Laboratories in a report on Friday, July 14th. Finally, TheStreet lowered shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $240.80.

Shares of Bio-Rad Laboratories (BIO) opened at 230.35 on Monday. The company’s 50-day moving average is $220.74 and its 200 day moving average is $217.89. Bio-Rad Laboratories has a 52 week low of $154.89 and a 52 week high of $242.79. The stock has a market capitalization of $6.83 billion, a P/E ratio of 455.24 and a beta of 0.93.

ILLEGAL ACTIVITY NOTICE: “Bio-Rad Laboratories, Inc. (BIO) Stock Rating Reaffirmed by Deutsche Bank AG” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/20/bio-rad-laboratories-inc-bio-stock-rating-reaffirmed-by-deutsche-bank-ag.html.

In other news, EVP Michael Crowley sold 700 shares of Bio-Rad Laboratories stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $215.91, for a total transaction of $151,137.00. Following the sale, the executive vice president now owns 2,060 shares in the company, valued at $444,774.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 28.29% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of BIO. Canada Pension Plan Investment Board purchased a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $113,000. Pacad Investment Ltd. purchased a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $113,000. Turner Investments LLC purchased a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $136,000. Capital Analysts LLC purchased a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $170,000. Finally, Meadow Creek Investment Management LLC raised its stake in shares of Bio-Rad Laboratories by 17.6% during the first quarter. Meadow Creek Investment Management LLC now owns 880 shares of the medical research company’s stock valued at $175,000 after purchasing an additional 132 shares during the period. Institutional investors own 62.84% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Stock Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related stocks with our FREE daily email newsletter.